The present disclosure provides antibodies that bind to human GFR±3 and methods of using same. According to certain embodiments, the antibodies are fully human antibodies that bind to human GFR±3. The antibodies described herein are useful for the treatment of diseases and disorders associated with one or more GFR±3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.
